Company Description
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions.
The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device.
Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Quang Pham |
Contact Details
Address: 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 United States | |
| Phone | 904 300 0701 |
| Website | cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001937993 |
| ISIN Number | US1276361086 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman and Chief Executive Officer |
| Jeffrey Cole | Chief Operating Officer |
| Dr. James J. Ferguson FACC, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 424B5 | Filing |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | 8-K | Current Report |
| Feb 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 29, 2025 | SCHEDULE 13D | Filing |
| Jan 15, 2025 | SCHEDULE 13G/A | Filing |